 <h1>Zanamivir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to zanamivir: inhalation disk</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, zanamivir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking zanamivir:</p><p>
<i>Rare</i>
</p><ul>
<li>Convulsions</li>
<li>dizziness and fainting</li>
<li>fast, slow, or irregular heartbeat</li>
<li>flushing or reddening of the skin</li>
<li>increased sensitivity to sunlight</li>
<li>itching, pain, redness, swelling, or watering of the eye or eyelid</li>
<li>joint pain</li>
<li>severe skin rash or hives</li>
<li>shortness of breath or troubled breathing</li>
<li>swelling or puffiness of the face</li>
<li>swollen glands or tightness in the throat</li>
<li>tightness in the chest or wheezing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of zanamivir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Change in hearing</li>
<li>cough</li>
<li>cough producing mucus</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>ear drainage</li>
<li>ear, nose, and throat infections</li>
<li>earache</li>
<li>fever or chills</li>
<li>headache</li>
<li>nasal signs and symptoms</li>
<li>nausea</li>
<li>pain and pressure over cheeks</li>
<li>pain in the ear</li>
<li>shortness of breath</li>
<li>vomiting</li>
</ul><p>
<!-- end inhalation disk --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zanamivir: inhalation powder</i></p><h3>General</h3><p>In clinical trials, the incidence of adverse events in patients treated with the inhalation powder was similar to that in the placebo (lactose vehicle) group.</p>
<p></p>
<p>The side effects reported most commonly with the IV formulation were elevated ALT, elevated AST, hepatocellular injury, diarrhea, and rash.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Inhalation powder:</p>
<p>-Very common (10% or more): Throat/tonsil discomfort/pain (up to 19%), cough (up to 17%), viral respiratory infections (up to 13%), nasal signs/symptoms (up to 12%)</p>
<p>-Common (1% to 10%): Sinusitis, bronchitis, ear/nose/throat infections, nasal inflammation, decline in forced expiratory volume in 1 second (FEV1)</p>
<p>-Frequency not reported: Bronchospasm-like events, congestion, rhinitis, dry throat, ear/nose/throat hemorrhage, asthma, exacerbation of asthma, respiratory arrest, lung tightness, decline in lung function, throat tightness/constriction</p>
<p>-Postmarketing reports: Bronchospasm, dyspnea<sup>[Ref]</sup></p><p>In a Phase 1 study, bronchospasm was reported in 1 of 13 patients with mild or moderate asthma (but without acute influenza-like illness) after administration of this drug.  In a Phase 3 study of patients with acute influenza-like illness and underlying asthma or chronic obstructive pulmonary disease, 24 of 244 patients on this drug (compared to 22 of 237 patients on placebo) experienced greater than 20% decline in FEV1 after 5 days of treatment.</p>
<p></p>
<p>Serious cases of bronchospasm (including fatalities) have been reported during therapy in patients with and without underlying airways disease.  Most of these cases were reported during postmarketing experience; causality was difficult to evaluate.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Inhalation powder:</p>
<p>-Very common (10% or more): Headaches (up to 24%)</p>
<p>-Common (1% to 10%): Dizziness</p>
<p>-Postmarketing reports: Seizures, syncope, vasovagal-like episodes shortly after inhalation</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Convulsions, depressed level of consciousness<sup>[Ref]</sup></p><h3>Other</h3><p>Inhalation powder:</p>
<p>-Common (1% to 10%): Malaise/fatigue, temperature regulation disturbances (fever/chills)</p>
<p>-Frequency not reported: Malaise, fatigue, fever</p>
<p>-Postmarketing reports: Facial edema</p>
<p></p>
<p>IV formulation:</p>
<p>-Uncommon (0.1% to 1%): Elevated alkaline phosphatase</p>
<p>-Frequency not reported: Oropharyngeal edema, facial edema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Inhalation powder:</p>
<p>-Common (1% to 10%): Muscle pain, musculoskeletal pain, arthralgia/articular rheumatism</p>
<p>-Frequency not reported: Myalgia, arthralgia, elevated creatine phosphokinase<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Inhalation powder:</p>
<p>-Frequency not reported: Urticaria</p>
<p>-Postmarketing reports: Rash, serious cutaneous reactions (e.g., erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), urticaria</p>
<p></p>
<p>IV formulation:</p>
<p>-Common (1% to 10%): Rash</p>
<p>-Uncommon (0.1% to 1%): Urticaria</p>
<p>-Frequency not reported: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Inhalation powder:</p>
<p>-Postmarketing reports: Allergic/allergic-like reactions (including oropharyngeal edema, serious skin rashes, anaphylaxis, anaphylactic/anaphylactoid reactions, facial edema)</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Anaphylactic/anaphylactoid reactions<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Abnormal behavior and delirium leading to injury, with fatal outcomes in some cases, with the use of this drug in influenza patients have been reported.  Although frequency was unknown, based on usage of this drug, these events appeared to be uncommon.  These events were primarily reported in pediatric patients and often had an abrupt onset and rapid resolution.  Since influenza may be associated with neurologic and behavioral symptoms (including hallucinations, delirium, and abnormal behavior, with fatal outcomes in some cases), contribution of this drug to these events was not established.</p><p>Inhalation powder:</p>
<p>-Postmarketing reports: Delirium, altered level of consciousness, confusion, abnormal behavior, delusions, hallucinations, agitation, anxiety, nightmares</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Abnormal behavior, hallucinations, delirium</p><h3>Gastrointestinal</h3><p>Inhalation powder:</p>
<p>-Common (1% to 10%): Diarrhea, nausea, vomiting, nausea/vomiting</p>
<p>-Frequency not reported: Abdominal pain</p>
<p></p>
<p>IV formulation:</p>
<p>-Common (1% to 10%): Diarrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Inhalation powder:</p>
<p>-Common (1% to 10%): Feeding problems (decreased/increased appetite, anorexia)</p>
<p>-Frequency not reported: Hyperkalemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Inhalation powder:</p>
<p>-Frequency not reported: Elevated liver enzymes</p>
<p></p>
<p>IV formulation:</p>
<p>-Common (1% to 10%): Elevated ALT, elevated AST, hepatocellular injury<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Inhalation powder:</p>
<p>-Frequency not reported: Lymphopenia, neutropenia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Inhalation powder:</p>
<p>-Frequency not reported: Hypotension</p>
<p>-Postmarketing reports: Arrhythmias<sup>[Ref]</sup></p><h3>Renal</h3><p>In 1 case report, acute renal failure, increased serum creatinine, hyperkalemia, and hypotension developed in a patient with multiple medical problems and multiple other medications.<sup>[Ref]</sup></p><p>Inhalation powder:</p>
<p>-Frequency not reported: Acute renal failure, increased serum creatinine<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Relenza (zanamivir)" Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cheer SM,  Wagstaff AJ "Zanamivir: an update of its use in influenza." Drugs 62 (2002): 71-106</p><p id="ref_5">5. Williamson JC, Pegram PS "Respiratory distress associated with zanamivir." N Engl J Med 342 (2000): 661-2</p><p id="ref_6">6. Laforce C,  Man CY,  Henderson FW, et al. "Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial." Clin Ther 29 (2007): 1579-1590</p><p id="ref_7">7. Montalto NJ, Gum KD, Ashley JV "Updated treatment for influenza A and B." Am Fam Physician 62 (2000): 2467-76</p><p id="ref_8">8. Moscona A "Neuraminidase inhibitors for influenza." N Engl J Med 353 (2005): 1363-73</p><p id="ref_9">9. Dreitlein WB, Maratos J, Brocavich J "Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza." Clin Ther 23 (2001): 327-55</p><p id="ref_10">10. Jefferson T,  Demicheli V,  Rivetti D,  Jones M,  Di Pietrantonj C,  Rivetti A "Antivirals for influenza in healthy adults: systematic review." Lancet 367 (2006): 303-13</p><p id="ref_11">11. Macdonald L "New influenza drugs zanamivir (Relenza (TM)) and oseltamivir (Tamiflu (TM)): unexpected serious reactions." Can Med Assn J 163 (2000): 879-81</p><p id="ref_12">12. Anekthananon T,  Pukritayakamee S,  Ratanasuwan W, et al. "Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks." J Antimicrob Chemother 68 (2013): 697-707</p><p id="ref_13">13. McNicholl IR,  McNicholl JJ "Neuraminidase inhibitors: zanamivir and oseltamivir." Ann Pharmacother 35 (2001): 57-70</p><p id="ref_14">14. Monto AS, Fleming DM, Henry D, et al. "Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections." J Infect Dis 180 (1999): 254-61</p></div>
<div class="more-resources" id="moreResources">
<h2>More about zanamivir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: inhaled anti-infectives</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zanamivir Inhalation, oral/nebulization &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Relenza</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Influenza</li>
<li>Influenza Prophylaxis</li>
<li>Swine Flu</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zanamivir: inhalation powder</i></p><h3>General</h3><p>In clinical trials, the incidence of adverse events in patients treated with the inhalation powder was similar to that in the placebo (lactose vehicle) group.</p><p></p><p>The side effects reported most commonly with the IV formulation were elevated ALT, elevated AST, hepatocellular injury, diarrhea, and rash.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Inhalation powder:</p><p>-Very common (10% or more): Throat/tonsil discomfort/pain (up to 19%), cough (up to 17%), viral respiratory infections (up to 13%), nasal signs/symptoms (up to 12%)</p><p>-Common (1% to 10%): Sinusitis, bronchitis, ear/nose/throat infections, nasal inflammation, decline in forced expiratory volume in 1 second (FEV1)</p><p>-Frequency not reported: Bronchospasm-like events, congestion, rhinitis, dry throat, ear/nose/throat hemorrhage, asthma, exacerbation of asthma, respiratory arrest, lung tightness, decline in lung function, throat tightness/constriction</p><p>-Postmarketing reports: Bronchospasm, dyspnea<sup>[Ref]</sup></p><p>In a Phase 1 study, bronchospasm was reported in 1 of 13 patients with mild or moderate asthma (but without acute influenza-like illness) after administration of this drug.  In a Phase 3 study of patients with acute influenza-like illness and underlying asthma or chronic obstructive pulmonary disease, 24 of 244 patients on this drug (compared to 22 of 237 patients on placebo) experienced greater than 20% decline in FEV1 after 5 days of treatment.</p><p></p><p>Serious cases of bronchospasm (including fatalities) have been reported during therapy in patients with and without underlying airways disease.  Most of these cases were reported during postmarketing experience; causality was difficult to evaluate.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Inhalation powder:</p><p>-Very common (10% or more): Headaches (up to 24%)</p><p>-Common (1% to 10%): Dizziness</p><p>-Postmarketing reports: Seizures, syncope, vasovagal-like episodes shortly after inhalation</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Convulsions, depressed level of consciousness<sup>[Ref]</sup></p><h3>Other</h3><p>Inhalation powder:</p><p>-Common (1% to 10%): Malaise/fatigue, temperature regulation disturbances (fever/chills)</p><p>-Frequency not reported: Malaise, fatigue, fever</p><p>-Postmarketing reports: Facial edema</p><p></p><p>IV formulation:</p><p>-Uncommon (0.1% to 1%): Elevated alkaline phosphatase</p><p>-Frequency not reported: Oropharyngeal edema, facial edema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Inhalation powder:</p><p>-Common (1% to 10%): Muscle pain, musculoskeletal pain, arthralgia/articular rheumatism</p><p>-Frequency not reported: Myalgia, arthralgia, elevated creatine phosphokinase<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Inhalation powder:</p><p>-Frequency not reported: Urticaria</p><p>-Postmarketing reports: Rash, serious cutaneous reactions (e.g., erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), urticaria</p><p></p><p>IV formulation:</p><p>-Common (1% to 10%): Rash</p><p>-Uncommon (0.1% to 1%): Urticaria</p><p>-Frequency not reported: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Inhalation powder:</p><p>-Postmarketing reports: Allergic/allergic-like reactions (including oropharyngeal edema, serious skin rashes, anaphylaxis, anaphylactic/anaphylactoid reactions, facial edema)</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Anaphylactic/anaphylactoid reactions<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Abnormal behavior and delirium leading to injury, with fatal outcomes in some cases, with the use of this drug in influenza patients have been reported.  Although frequency was unknown, based on usage of this drug, these events appeared to be uncommon.  These events were primarily reported in pediatric patients and often had an abrupt onset and rapid resolution.  Since influenza may be associated with neurologic and behavioral symptoms (including hallucinations, delirium, and abnormal behavior, with fatal outcomes in some cases), contribution of this drug to these events was not established.</p><p>Inhalation powder:</p><p>-Postmarketing reports: Delirium, altered level of consciousness, confusion, abnormal behavior, delusions, hallucinations, agitation, anxiety, nightmares</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Abnormal behavior, hallucinations, delirium</p><h3>Gastrointestinal</h3><p>Inhalation powder:</p><p>-Common (1% to 10%): Diarrhea, nausea, vomiting, nausea/vomiting</p><p>-Frequency not reported: Abdominal pain</p><p></p><p>IV formulation:</p><p>-Common (1% to 10%): Diarrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Inhalation powder:</p><p>-Common (1% to 10%): Feeding problems (decreased/increased appetite, anorexia)</p><p>-Frequency not reported: Hyperkalemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Inhalation powder:</p><p>-Frequency not reported: Elevated liver enzymes</p><p></p><p>IV formulation:</p><p>-Common (1% to 10%): Elevated ALT, elevated AST, hepatocellular injury<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Inhalation powder:</p><p>-Frequency not reported: Lymphopenia, neutropenia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Inhalation powder:</p><p>-Frequency not reported: Hypotension</p><p>-Postmarketing reports: Arrhythmias<sup>[Ref]</sup></p><h3>Renal</h3><p>In 1 case report, acute renal failure, increased serum creatinine, hyperkalemia, and hypotension developed in a patient with multiple medical problems and multiple other medications.<sup>[Ref]</sup></p><p>Inhalation powder:</p><p>-Frequency not reported: Acute renal failure, increased serum creatinine<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Relenza (zanamivir)" Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cheer SM,  Wagstaff AJ "Zanamivir: an update of its use in influenza." Drugs 62 (2002): 71-106</p><p id="ref_5">5. Williamson JC, Pegram PS "Respiratory distress associated with zanamivir." N Engl J Med 342 (2000): 661-2</p><p id="ref_6">6. Laforce C,  Man CY,  Henderson FW, et al. "Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial." Clin Ther 29 (2007): 1579-1590</p><p id="ref_7">7. Montalto NJ, Gum KD, Ashley JV "Updated treatment for influenza A and B." Am Fam Physician 62 (2000): 2467-76</p><p id="ref_8">8. Moscona A "Neuraminidase inhibitors for influenza." N Engl J Med 353 (2005): 1363-73</p><p id="ref_9">9. Dreitlein WB, Maratos J, Brocavich J "Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza." Clin Ther 23 (2001): 327-55</p><p id="ref_10">10. Jefferson T,  Demicheli V,  Rivetti D,  Jones M,  Di Pietrantonj C,  Rivetti A "Antivirals for influenza in healthy adults: systematic review." Lancet 367 (2006): 303-13</p><p id="ref_11">11. Macdonald L "New influenza drugs zanamivir (Relenza (TM)) and oseltamivir (Tamiflu (TM)): unexpected serious reactions." Can Med Assn J 163 (2000): 879-81</p><p id="ref_12">12. Anekthananon T,  Pukritayakamee S,  Ratanasuwan W, et al. "Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks." J Antimicrob Chemother 68 (2013): 697-707</p><p id="ref_13">13. McNicholl IR,  McNicholl JJ "Neuraminidase inhibitors: zanamivir and oseltamivir." Ann Pharmacother 35 (2001): 57-70</p><p id="ref_14">14. Monto AS, Fleming DM, Henry D, et al. "Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections." J Infect Dis 180 (1999): 254-61</p><h2>More about zanamivir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: inhaled anti-infectives</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zanamivir Inhalation, oral/nebulization &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Influenza</li>
<li>Influenza Prophylaxis</li>
<li>Swine Flu</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>